Floatz logo

Brentuximab Vedotin

Recurrent Follicular T-Cell Lymphoma

Northwestern Universityantibody_drug_conjugatePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the Recurrent Follicular T-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Pralatrexate
Corvus Pharmaceuticals, Inc.
Phase 3BB
FILGRASTIM
City of Hope Medical Center
Phase 3B
Soquelitinib
Corvus Pharmaceuticals, Inc.
Phase 3B
Pembrolizumab
Northwestern University
Phase 2B
Cyclophosphamide
City of Hope Medical Center
Phase 2B

View all 18 →

Same molecule, other indications

Brentuximab Vedotin is also rated in:

T-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →
anaplastic large cell lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →